Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
Claim Interpretation
Claim 1 recites “2-1”, “2-2”, “3-1”, and “3-2” in the limitation of the second and third repeating units. “2-1” will be interpreted as meaning repeating unit 2-component 1, and this interpretation will be applied similarly for “2-2”, “3-1”, and “3-2”. The examiner suggests that for clarity, these components be put in parentheses or relabeled, i.e. (2-1) or 2-a.
Claim 4 recites a molar ratio for the third repeating unit. This will be interpreted as being in relation to the whole of three listed repeat units of the copolymer composition.
Double Patenting
The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).
A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b).
The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13.
The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer.
Claim 1 rejected on the ground of nonstatutory double patenting as being unpatentable over claim 9 of U.S. Patent No. US 12,570,794 B2, hereafter ’794. Although the claims at issue are not identical, they are not patentably distinct from each other because the limitations in the application are clearly taught by '794.
Claim 9 of ‘794 differs from claim 1 of this application in that the reference claim does not recite 2-2 or 3-2 and recites the use of an organic filler. Nevertheless, the application’s claim falls within the scope of claim 1 of ‘794 and therefore the claims are not patently distinct.
Claim Rejections - 35 USC § 102
In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status.
The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:
A person shall be entitled to a patent unless –
(a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention.
(a)(2) the claimed invention was described in a patent issued under section 151, or in an application for patent published or deemed published under section 122(b), in which the patent or application, as the case may be, names another inventor and was effectively filed before the effective filing date of the claimed invention.
Claim(s) 1, 4, and 9 is/are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Ren et al. (AU 2011231640 A1), hereafter referred to as Ren.
Regarding claim 1, Ren teaches a copolymer comprised of dicarboxylic acid component A, further comprised of components a2 and a1, and diol component B (pg. 20-21, lines 31-39, 1-6). Component a2 is preferentially comprised of terephthalic acid-based monomers, like terephthalic acid and/or dimethyl terephthalate, which read on the claimed first repeating unit (pg. 23, lines 6-9). Component a1 is selected from an aliphatic dicarboxylic acids, preferably adipic acid and ester-forming derivatives, which read on the claimed second repeating unit (pg. 22, lines 17-19, 35-37). Diol component B is selected from alkanediols, including 1,2-butanediol and 1,4-butanediol and mixtures of selected diols, which read on the claimed third repeating unit (pg. 23, lines 25, 30, 36).
Regarding claim 4, Ren teaches the copolymer discussed above (10), where the molar ratio between components A and B to be preferably from 0.6:1 to .99:1 (pg. 21, lines 16-17). This ratio correlates to component B comprising 50.5-62.5 mol% of the three claimed repeating units. Ren’s range overlaps with sufficient specificity to anticipate the claimed range. For more information, see MPEP § 2131.03.
Regarding claim 9, Ren teaches the copolymer discussed above (10), where the weight-average molecular weight ranges from 40 to 2500 kDa (pgs. 18, 31, lines 6-7, 37-38). Ren additionally teaches production example 10, using 1,4-butanediol, terephthalic acid, and adipic acid according to production example 1 (pgs. 39-40, lines 36-42, 1-9), where example 10’s produced copolymer has a weight-average molecular weight of 76.3 kDa (pg. 44, Table 3). Ren discloses a point within the claimed range, and so Ren anticipates the claim. For more information, see MPEP § 2131.03.
Claim Rejections - 35 USC § 102/103
In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status.
The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action:
A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made.
The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows:
1. Determining the scope and contents of the prior art.
2. Ascertaining the differences between the prior art and the claims at issue.
3. Resolving the level of ordinary skill in the pertinent art.
4. Considering objective evidence present in the application indicating obviousness or nonobviousness.
This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention.
Claim(s) 3 and 7 is/are rejected under 35 U.S.C. 102(a)(1) as anticipated by or, in the alternative, under 35 U.S.C. 103 as obvious over Ren.
Regarding claim 3, Ren teaches the copolymer discussed above (10), where component A is preferably of a scheme where component a1 is 40-90 mol% and component a2 is 10-60 mol%, where the total molar percentages of the two components is 100% (pg. 21, lines 27-34). This would correlate to a ratio of a1:a2 or instant second repeating unit : instant first repeating unit being approximately 2:3 (.67:1) to 9:1. Ren’s range overlaps with sufficient specificity to anticipate the claimed range. For more information, see MPEP § 2131.03.
Alternatively, Ren’s disclosed range overlaps with the claimed range. In the case where the claimed ranges overlap or lie inside ranges disclosed by the prior art a prima facie case of obviousness exists. For more information, see MPEP § 2144.05.
Regarding claim 7, Ren teaches the copolymer discussed above (10), where diol component B can be selected from taught suitable diols including 1,2-butanediol and 1,4-butanediol (pg. 23, lines 29-30). Ren teaches that these selected diols can also be used in mixture with each other (pg. 23, lines 36-38). This mixture would read on the instant’s third repeating unit comprised of 1,2-butanediol and 1,4-butanediol.
Alternatively, Ren teaches the mixture of suitable diols, including 1,2-butanediol and 1,4-butanediol. It would have been obvious to one of ordinary skill in the art at the time of filing to combine 1,2- and 1,4-butanediol, as they are recognized by the prior art as equivalents suitable for the same purpose (i.e. as alkanediols suitable for forming Ren’s polyester). It is prima facie obvious to combine equivalents known for the same purpose. See MPEP 2144.06(I).
Claim Rejections - 35 USC § 103
Claim(s) 2 and 5 is/are rejected under 35 U.S.C. 103 as being unpatentable over Ren.
Regarding claim 2, Ren teaches the copolymer discussed above (10), where component a1 can be selected from linear and branched 4 to 8 carbon aliphatic dicarboxylic acids (pg. 22, lines 17-19). Suitable dicarboxylic acids include 3-methylglutaric acid (p. 22, lines 24-25). 3-Methylglutaric acid and 3-methyladipic acid are homologs differing by the successive addition of the same chemical group, in this case a -CH2- group. Homologs are generally of sufficiently close structural similarity that there is a presumed expectation that such compounds possess similar properties.
Additionally, Ren’s 3-methylglutaric acid and the claimed 3-adipic acid have similar utility in that both are employed as aliphatic dicarboxylic acid monomers used in combination with terephthalic acid and one or more additional diols including butanediol to form a polyester. Ren also teaches the selection of 1,2-butanediol as component B (pg. 23, lines 29-30).
A prima facie case of obviousness may be made when chemical compounds have very close structural similarities and similar utilities. An obviousness rejection based on similarity in chemical structure and function entails the motivation of one skilled in the art to make a claimed compound, in the expectation that compounds similar in structure will have similar properties. See MPEP 2144.09.
It would have been obvious to one of ordinary skill in the art at the time of the invention to modify Ren to select 3-methyladipic acid as a homolog of 3-methylglutaric acid, as the two species are expected to possess similar properties and have similar utility. Modification in this way, along with the inclusion of Ren’s 1,2-butanediol, reads on Claim 2.
Regarding claim 5, Ren teaches the copolymer discussed above (10), where component a1 can be selected from linear and branched 4 to 8 carbon aliphatic dicarboxylic acids (pg. 22, lines 17-19). 3-Methylglutaric acid and 3-methyladipic acid are homologs differing by the successive addition of the same chemical group, in this case a -CH2- group. Homologs are generally of sufficiently close structural similarity that there is a presumed expectation that such compounds possess similar properties.
Additionally, Ren’s 3-methylglutaric acid and the claimed 3-adipic acid have similar utility in that both are employed as aliphatic dicarboxylic acid monomers used in combination with terephthalic acid and one or more additional diols including butanediol to form a polyester. While 3-methyladipic acid is not explicitly claimed, one of ordinary skill would see that a similar structure is contemplated in the taught 3-methylglutaric acid and it would be prima facie obvious prior to the effective filing date of the instant application to employ 3-methyladipic acid in as a branched, ester-forming variant embodiment of the preferred embodiment (adipic acid) of the polymer component (pg. 22, lines 24-25, 28-32, 35-37).
Ren also teaches that mixtures can be made of at least one aliphatic dicarboxylic acid. The mixture of the 3-methyladipic acid and the adipic acid would have also been prima facie obvious to a person of ordinary skill in the art to employ a grouping of similar aliphatic dicarboxylic acids, especially when one of the two is taught as particularly preferred (pg. 22, line 35).
Claim(s) 6 and 8 is/are rejected under 35 U.S.C. 103 as being unpatentable over Ren as applied to claims 1, 5, and 7 above, and further in view of Garcia et al. (US 20200002487 A1), hereafter referred to as Garcia.
Regarding claim 6, Ren teaches the copolymer as discussed above (10), with an embodiment obvious to a person skilled in the art discussed in (25-27), relevant to claim 5. Briefly, the use of and combination of 3-methyladipic acid with adipic acid would be obvious to given Ren teaches the use of branched 4 to 8 carbon aliphatic dicarboxylic acids. Ren does not teach a ratio for these dicarboxylic acids.
Garcia teaches a polyester polymer comprised of a dicarboxylic acid comprised of 70-100 mol% of units derived from succinic acid (a1) and 3-20 mol% of dicarboxylic acid different from succinic acid (a2), with molar percentages relative to the total dicarboxylic acid component (pg. 1, [0009-0012]). The polymer is also comprised of a diol component, where 95-100 mol% of the total moles of diol are from 1,4-butanediol (b1), and 0-5 mol% from another saturated aliphatic diol different from 1,4-butanediol (pg. 1, [0013-0015]). Component a2 is taught to have adipic acid preferably selected as the 4 to 11 carbon saturated aliphatic dicarboxylic acid (pg. 2, [0045]). Garcia also teaches that the polyester includes aromatic dicarboxylic acids, preferably terephthalic acid (pg. 2, [0047]). Garcia does not teach the use of 3-methyladipic acid.
While Ren does not teach ratios for the mixture or combination dicarboxylic acids like adipic or 3-methyladipic acid, and while of Garcia teaches the use of succinic and adipic acid (pg. 2, [0045]), with the teachings of Ren in view of Garcia, it would have been obvious to one of ordinary skill in the art prior to the effective filing date of the instant application to employ Garcia’s taught ratios to other similar aliphatic dicarboxylic acids in the creation of a degradable polybutylene adipate terephthalate at ambient temperatures (pg. 8, [0137]).
Regarding claim 8, Ren teaches the copolymer as discussed above (10), with an embodiment obvious to a person skilled in the art discussed in (19), relevant to claim 7. Briefly, the use of and combination of 3-methyladipic acid with adipic acid would be obvious to given Ren teaches the use of branched 4 to 8 carbon aliphatic dicarboxylic acids. Ren does not teach a ratio for these dicarboxylic acids.
Garcia teaches a polyester polymer comprised of a dicarboxylic acid comprised of 70-100 mol% of units derived from succinic acid (a1) and 3-20 mol% of dicarboxylic acid different from succinic acid (a2), with molar percentages relative to the total dicarboxylic acid component (pg. 1, [0009-0012]). The polymer is also comprised of a diol component, where 95-100 mol% of the total moles of diol are from 1,4-butanediol (b1), and 0-5 mol% from another saturated aliphatic diol different from 1,4-butanediol (pg. 1, [0013-0015]). Component a2 is taught to have adipic acid preferably selected as the 4 to 11 carbon saturated aliphatic dicarboxylic acid (pg. 2, [0045]). Garcia also teaches that the polyester includes aromatic dicarboxylic acids, preferably terephthalic acid (pg. 2, [0047]).
While Ren does not teach ratios for the mixture or combination alkanediols like 1,4-butanediol or 1,2-butanediol, with the teachings of Ren in view of Garcia, it would have been obvious to one of ordinary skill in the art prior to the effective filing date of the instant application to employ Garcia’s taught ratios to other similar alkanediols in the creation of a degradable polybutylene adipate terephthalate (pg. 8, [0137]).
Conclusion
The prior art made of record and not relied upon is considered pertinent to applicant's disclosure.
Volker et al. (US 5889135 A) teaches a degradable thermoplastic polybutylene adipate terephthalate composition comprised of C2-C6 alkanediols.
Nishida et al. (JP 2005169815 A, machine translation) teaches a lactic acid-based resin comprised of terephthalic acid, 3-methyladipic acid, and 1,4-butanediol.
Tanaka et al. (US 20070203287 A1) teaches a lactic acid-based resin comprised of terephthalic acid, 3-methyladipic acid, and 1,4-butanediol.
Effenberger et al. (US 20090250831 A1) teaches a polycondensation product of terephthalic acid, 1,4-butanediol, 12-butanediol, and another dicarboxylic acid.
Any inquiry concerning this communication or earlier communications from the examiner should be directed to ARMAN M. FARAZDAGHI whose telephone number is (571)270-5813. The examiner can normally be reached Monday - Friday, Monday - Thursday, 8:30 am - 5:00 pm.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Robert Jones can be reached at (571) 270-7733. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/ARMAN M. FARAZDAGHI/Examiner, Art Unit 1762
/ROBERT S JONES JR/Supervisory Patent Examiner, Art Unit 1762